AscellaHealth Launches Strategic Pharmacy Benefits Enablement Platform to Address 2026 Healthcare Cost and Access Challenges
Globe Newswire • Fri Jan 16 2026
BERWYN, Pa., Jan. 14, 2026 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions for the specialty pharmaceutical industry, today announced the launch of AscellaOne™, a technology-driven strategic enablement platform designed to modernize how health plans, employers and PBM organizations administer and manage pharmacy benefits.
BERWYN, Pa., Jan. 14, 2026 (GLOBE NEWSWIRE) – AscellaHealth, a global partner delivering customizable solutions for the specialty pharmaceutical industry, today announced the launch of AscellaOne™, a technology-driven strategic enablement platform designed to modernize how health plans, employers and PBM organizations administer and manage pharmacy benefits. AscellaOne seamlessly connects payers and vendor partners through a modular, interoperable ecosystem—delivering the economics and capabilities of traditional, large national PBMs without being one, while providing the transparency, flexibility and control that employers and health plans increasingly demand.
To read more, click here
About AscellaHealth
Healthcare today is more complex than ever—especially when it comes to therapies for people living with rare and chronic conditions. These high-cost, high-impact treatments account for only a small fraction of prescriptions, but they make up the largest and fastest-growing share of total drug spend. As a result, balancing affordability and quality of care remains a significant challenge.
We’re here to change that.
Because at AscellaHealth, we believe that all patients in need should have the ability to access life-changing therapies.
Our Core Beliefs
At AscellaHealth, patients are not just part of the process—they’re why we do what we do. Every solution we build and every partnership we form is designed with the patient in mind.
Patients First, Always.
Balancing Cost and Care.
Better Stakeholder Outcomes.